Evidence map›Paper›PMID 27858169›Full record

ArticleJournal of industrial microbiology & biotechnology2017

A novel mechanism of immunity controls the onset of cinnamycin biosynthesis in Streptomyces cinnamoneus DSM 40646.

Sean O'Rourke, David Widdick, Mervyn Bibb

Open access · hybridAbstract read
In one paragraph

Article in Journal of industrial microbiology & biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Discovery of Coerumycin, a Cinnamycin-like Lantibiotic fromAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Applied and environmental microbiology · 2020
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Insights into the Biosynthesis of Duramycin.Applied and environmental microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sean O'RourkeDepartment of Molecular Microbiology, John Innes Centre, Norwich, UK.
David WiddickDepartment of Molecular Microbiology, John Innes Centre, Norwich, UK.
Mervyn BibbDepartment of Molecular Microbiology, John Innes Centre, Norwich, UK. mervyn.bibb@jic.ac.uk.ORCID 0000-0002-7289-6745
John Innes Centre · GB

Funding

Biotechnology and Biological Sciences Research Council 208/P08242Biotechnology and Biological Sciences Research Council APG20593Biotechnology and Biological Sciences Research Council BB/J004561/1
6 · The paper itself

Abstract

Streptomyces cinnamoneus DSM 40646 produces the Class II lantibiotic cinnamycin which possesses an unusual mechanism of action, binding to the membrane lipid phosphatidylethanolamine (PE) to elicit its antimicrobial activity. A comprehensive analysis of the cinnamycin biosynthetic gene cluster has unveiled a novel mechanism of immunity in which the producing organism methylates its entire complement of PE prior to the onset of cinnamycin production. Deletion of the PE methyl transferase gene cinorf10, or the two-component regulatory system (cinKR) that controls its expression, leads not only to sensitivity to the closely related lantibiotic duramycin, but also abolishes cinnamycin production, presumably reflecting a fail-safe mechanism that serves to ensure that biosynthesis does not occur until immunity has been established.

Indexed as

Gene Expression Regulation, BacterialGenes, BacterialBacterial ProteinsBacteriocinsBase SequenceGene DeletionMultigene FamilyPeptidesPeptides, CyclicPhosphatidylethanolaminesStreptomycesBacterial ProteinsBacteriocinscinnamycinduramycinPeptidesPeptides, CyclicphosphatidylethanolaminePhosphatidylethanolaminesInductionLantibioticPhosphatidylethanolamineRegulationResistance

Identifiers

PMID27858169
PMCPMC5408092
OpenAlexW2554967355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.